Eidos Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019
Eidos Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported loss from operations of $12,584,000 against $7,997,000 a year ago. Net loss attributable to common stockholders was $11,733,000 against $7,963,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.32 against $1.81 a year ago.